 Applied DNA Sciences Inc NASDAQ: APDN reported a more than ninefold YY increase in Q4 FY21 revenues, driven by the rise in clinical laboratory service revenues related to COVID-19 testing. For Q4, the firm reported 3.0 million in revenues, up from 314,000 a year ago, beating the consensus Wall Street estimate of 2.3 million. 